Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseasesMichael Benatar, Volkan Granit, Anne‐Laure Grignon et al.|Brain|2021Cited by 116
Mild motor impairment as prodromal state in amyotrophic lateral sclerosis: a new diagnostic entityMichael Benatar, Joanne Wuu, Volkan Granit et al.|Brain|2022Cited by 57
Prognostic clinical and biological markers for amyotrophic lateral sclerosis disease progression: validation and implications for clinical trial design and analysisMichael Benatar, Eric A. Macklin, Andrea Malaspina et al.|EBioMedicine|2024Cited by 43
Defining cognitive impairment in amyotrophic lateral sclerosis: an evaluation of empirical approachesCorey T. McMillan, Michael Benatar, Joanne Wuu et al.|Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration|2022Cited by 41
The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biologyMichael Benatar, Tahseen Mozaffar, Joanne Wuu et al.|Nature Reviews Neurology|2024Cited by 40